A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Researchers from Washington State University and the Department of Energy’s Pacific Northwest National Laboratory (PNNL) used tiny tubes made from organic molecules called peptoids to deliver cancer-killing drugs in a targeted manner. The research, led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chun-Long Chen, a senior research scientist at PNNL and a joint faculty fellow at the University of Washington, was published as the cover story in the prestigious journal Small.
The biologically-inspired nanotubes, which are about a hundred thousand times thinner than a human hair, were rolled up from membrane-like nanosheets. The drug molecules, fluorescent dyes and cancer-targeting molecules were precisely placed within the nanotubes, enabling them to track the efficiency of drug delivery into the cancer cells.
The new technology allows the two drugs – one for chemotherapy and the other for a less-invasive photodynamic therapy treatment – to be delivered directly to the cancer cells. Photodynamic therapy uses a chemical that, when exposed to light, releases reactive oxygen species (ROS) that kill cancer cells. The researchers’ dual-drug approach enabled the use of a lower dose of the cancer drugs than using a single drug, leading to effective killing of cancer cells with low toxicity.
“By precisely engineering these nanotubes with fluorescent dyes and cancer targeting molecules, scientists can clearly locate tumor cells and track how the drug regimen is performing,” said Lin. “We can also track how nanotubes enter and deliver the drugs inside the cancer cell.”
The team tested the nanotubes on lung cancer cells and found that they delivered the chemotherapy drug doxorubicin directly into the fast-dividing cancer cells, resulting in highly efficient cancer killing while using less chemotherapy drugs.
“This is a promising approach for precision targeting with little damage to healthy surrounding cells,” said Lin.
While other nanomaterials, such as carbon nanotubes, have been used to deliver and track cancer-killing drugs, researchers have found that they are toxic to the body. Furthermore, they didn’t do well at precisely recognizing molecules.
“By using these peptoids, we were able to develop highly programmable nanotubes and a biocompatible delivery mechanism,” said Chen. “We also harnessed the high stability of peptoid and its well-controlled packing to develop nanotubes that are highly stable.”
“Due to their unique structure, these nanotubes can be easily assembled for use in cancer therapy and stay in the body longer for treatment,” said Lin.
The team is now looking for collaboration and funding opportunities with pharmaceutical companies to extend the research into animal and clinical studies.
The Latest on: Lung cancer
via Google News
The Latest on: Lung cancer
- Lung Cancer: Can Discrepancy in HLA Expression Predict Lack of Response to Checkpoint Inhibitors?on June 23, 2020 at 3:13 pm
A group from the Mayo Clinic tested this hypothesis, by quantifying HLA-A IHC expression on paired primary and metastatic brain tumors in patients with metastatic non-small cell lung cancer (NSCLC).
- Jarring Discordance Between Idealized and Real-World Management in Stage III Non–Small-Cell Lung Canceron June 23, 2020 at 1:07 pm
The setting of stage III, locally advanced, non–small-cell lung cancer (NSCLC) is one in which the limited available evidence suggests that there is an understudied disparity between the standards ...
- Racial disparities seen in PET/CT imaging for lung canceron June 23, 2020 at 11:32 am
Black and Hispanic patients are less likely to undergo guideline-recommended imaging at diagnosis of non-small cell lung cancer, according to a study recently published in the Journal of the National ...
- Highlights in Non–Small Cell Lung Cancer From ASCO 2020on June 23, 2020 at 10:10 am
Dr Mark Kris reports on key studies in NSCLC from ASCO 2020, including the practice-changing ADAURA trial, results on an antibody-drug conjugate targeting HER2, and data on a new checkpoint inhibitor.
- BRIEF-Thermo Fisher, Daiichi Sankyo To Co-Develop Global Companion Diagnostic For Non-Small Cell Lung Canceron June 23, 2020 at 9:19 am
THERMO FISHER SCIENTIFIC AND DAIICHI SANKYO TO CO-DEVELOP GLOBAL COMPANION DIAGNOSTIC FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER * THERMO FISHER SCIENTIFIC - WILL RETAIN RIGHTS TO COMMERCIALIZE TEST ...
- Onconova Initiates Phase I/IIa Study on Lung Cancer Candidateon June 23, 2020 at 8:28 am
Onconova Therapeutics, Inc. ONTX announced that it has commenced an investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb’s BMY Opdivo (nivolumab) in advanced ...
- Lung Cancer Registry Launches Landmark Survey on Women's Sexual Healthon June 23, 2020 at 5:51 am
The Lung Cancer Registry has launched a landmark new survey on the impact of lung treatments on women's sexual health. The aim is to explore the magnitude of the problem and give researchers and ...
- LUNGevity and EGFR Resisters Collaborate on Lung Cancer Research Awardson June 22, 2020 at 12:44 pm
LUNGevity Foundation is partnering with patient-led group EGFR Resisters on the EGFR-Positive Lung Cancer Research Award Program.
- Study Examines Community-based Lung Cancer Screeningon June 22, 2020 at 11:27 am
Results of a recent Annals of Family Medicine study indicate that under the right conditions, lung cancer screenings can be performed safely and effectively in the community health setting.
- Lung Cancer Research Foundation Names Dr. Trudy Oliver to its Scientific Advisory Boardon June 22, 2020 at 7:59 am
PR Newswire NEW YORK, June 22, 2020 NEW YORK, June 22, 2020 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) today announced that Dr. Trudy Oliver has joined its Scientific Advisory Board.
via Bing News